

Ferromyn for the speedy oral correction of all iron-deficiency states : The use of stabilized Trypsin : a new treatment for ulcers abrasions burns pyodermias.

Contributors

Calmic Ltd.

Publication/Creation

[1957?]

Persistent URL

<https://wellcomecollection.org/works/syccgepj>

License and attribution


Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



Wellcome Collection
183 Euston Road
London NW1 2BE UK
T +44 (0)20 7611 8722
E library@wellcomecollection.org
<https://wellcomecollection.org>

"... and unless the patient is very near term, this (FERROMYN 1 t.d.s.) is the method of choice in the first instance, even for severe degrees of iron-deficiency anæmia"

Ref: *BMJ* (1956) 2,638



FERROMYN for the speedy oral
correction of all
iron-deficiency states

FERROMYN is presented in four forms:
FERROMYN TABLETS AND FERROMYN ELIXIR.
Each tablet/teaspoonful contains:
Ferrous Succinate 150 mg.
FERROMYN 'B' TABLETS AND ELIXIR FERROMYN 'B'.
Each tablet/teaspoonful contains:
Ferrous Succinate 150 mg. Aneurine Hydrochloride 1 mg. Riboflavin 1 mg. Nicotinamide 10 mg.

CALMIC LIMITED, CREWE
Phone CREWE 3251-5

FERROMYN

LONDON :
2 Mansfield St., W.1. Phone LANgham 8038-9

AUSTRALIA : 458-468 Wattle St., Ultimo, Sydney. N.S.W.

CANADA : Terminal Building, York St., Toronto.

The use of stabilized Trypsin

A NEW TREATMENT

FOR **ULCERS**

ABRASIONS

BURNS

PYODERMAS



ANY MEDICAL PRACTITIONER knows how stubbornly resistant to any therapy a long-standing varicose ulcer can be. The reason is partly the diminished blood supply, but more perhaps the formation of a pus-containing layer and of crusts which cover the ulcer and impede the healing process. Similar difficulties are often encountered in the treatment of wounds and abrasions.

PROTEOLYTIC ACTION

It has long been known that the proteolytic enzyme Trypsin could digest crusts by the process of physiological curettage. The difficulty has been to incorporate the trypsin in a stable preparation. In Biotrase trypsin remains active physiologically for over one year. A certificate of stability has been issued by a leading Institute of Bio-chemistry. It rapidly dissolves crusts and scabs and leaves a clean, granulating surface.

Biotrase has been designed by Lloyd-Hamol of London and Zurich for the treatment of infected skin lesions. Apart from trypsin, it contains two new antiseptic agents of proved bacteriolytic properties, Ca-N-Hydroxymethyl-

ylglutamate and 2,2¹ thiobis-(4,6-dichlorophenol) designated bithionol, both of which are effective against a wide range of gram-positive and gram-negative pathogenic organisms and do not cause skin sensitivity. Biotrase also contains Carbamide, included for its buffering properties.

INDICATIONS FOR USE

Biotrase may be used wherever there is an infected—or potentially infected—breach of surface of the skin. Common conditions for its use include the following: Varicose, diabetic and post-thrombotic ulcers; wounds, and second and third degree burns; infected and necrotic skin conditions, including pyoderma; boils and carbuncles (following incision).

COMPOSITION OF BIOTRASE

Trypsin pur.	0.16%
Ca-N-Hydroxymethylglutamate	5.00%
2,2 ¹ thiobis-(4,6-dichlorophenol)	0.50%
Carbamide B.P.	5.00%
In polyethylene glycol	

Biotrase is available in 35g. tubes at a basic N.H.S. price of 3/9d. plus Purchase Tax. Samples and literature are available to medical practitioners on request.

Biotrase

'Biotrase' is a registered trade mark of
LLOYD-HAMOL LIMITED
11 Waterloo Place, London, S.W.1.